Company Filing History:
2 out of 5 
1 out of 2 Years Active: 2022
Title: Innovations of Shengmei Wen in Biotech
Introduction
Shengmei Wen is a prominent inventor based in Beijing, China. He has made significant contributions to the field of biotechnology, particularly in the development of bispecific antibodies and monoclonal antibodies. With a total of 2 patents, his work focuses on innovative treatments for various diseases.
Latest Patents
One of his latest patents is the "Anti-EGFR and anti-CD3 bispecific antibody and uses thereof." This invention provides a bispecific antibody that can specifically bind to the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 molecule on immune cells. The antibody is designed to treat tumor diseases associated with high or abnormal expression of EGFR. Additionally, he has developed a preparation method for this bispecific antibody, which has shown high affinity and potential clinical applications.
Another significant patent is the "Anti-PCSK9 monoclonal antibody." This application discloses a monoclonal antibody that targets Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). The antibody is derived from a phage antibody library and has been screened for high affinity. It is intended for treating dyslipidemia, cardiovascular diseases, and thrombotic occlusion diseases by inhibiting the binding of PCSK9 with its ligand.
Career Highlights
Shengmei Wen has worked with notable companies such as Beijing Dongfang Biotech Co., Ltd. and Beijing Jingyitaixiang Technology Development Co. Ltd. His experience in these organizations has contributed to his expertise in biotechnology and antibody development.
Collaborations
Throughout his career, Shengmei has collaborated with esteemed colleagues, including Yi Bai and Wen Tao Zhang. These partnerships have fostered innovation and advancement in his research endeavors.
Conclusion
Shengmei Wen's contributions to biotechnology through his patents and collaborations highlight his role as a leading inventor in the field. His work continues to pave the way for innovative treatments that address critical health challenges.